Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach

Restricted access

Testicular cancer is the most common cancer in men aged 15 to 40 years in the United States, Canada, and many European countries. Given the excellent prognosis of most men with testicular cancer, updates in care after treatment have become very important. This article provides a review of the available evidence, integrated with expert medical judgment, in the area of testicular cancer follow-up.

Correspondence: Clair J. Beard, MD, Dana-Farber Cancer Institute/Brigham and Women's Hospital, 75 Francis Street, ASB-1, Level 2, Boston, MA 02115. E-mail: cbeard@lroc.harvard.edu
  • 1.

    NigamMAschebrook-KilfoyBShikanovSEggenerS. Increasing incidence of testicular cancer in the United States and EuropeWorld J Urol2015;33:623631.

    • Search Google Scholar
    • Export Citation
  • 2.

    RosenAJayramGDrazerMEggenerSE. Global trends in testicular cancer incidence and mortality. Eur Urol2011;60:374379.

  • 3.

    PowerDABrownRSBrockCS. Trends in testicular carcinoma in England and Wales, 1971-99. BJU Int2001;87:361365.

  • 4.

    DaugaardGGundgaardMGMortensenMS. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol2014;32:38173823.

    • Search Google Scholar
    • Export Citation
  • 5.

    KollmannsbergerCTandstandTBedardPL. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol2015;33:5157.

    • Search Google Scholar
    • Export Citation
  • 6.

    GrollRJWardePJewettMA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol2007;64:182197.

    • Search Google Scholar
    • Export Citation
  • 7.

    VespriniDChungPTolanS. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer2012;118:52455250.

  • 8.

    MotzerRJJonaschEAgarwalN. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 22015. Available at: NCCN.org. Accessed May 27 2015.

    • Search Google Scholar
    • Export Citation
  • 9.

    YuHYMadisonRASetodjiCMSaigalCS. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol2009;27:43274332.

  • 10.

    ErnstDSBrasherPVennerPM. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol2005;12(2):2575-80.

    • Search Google Scholar
    • Export Citation
  • 11.

    FreedmanLSJonesWGPeckhamMJ. Histopathology in the prediction of relapse of patients with stage i testicular teratoma treated by orchidectomy alone. Lancet1987;330:294298.

    • Search Google Scholar
    • Export Citation
  • 12.

    OndrusDMatoskaJBelanV. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol1998;33:562566.

    • Search Google Scholar
    • Export Citation
  • 13.

    FreedmanLSParkinsonMCJonesWG. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet1987;2:294298.

    • Search Google Scholar
    • Export Citation
  • 14.

    AlbersPSienerRKlieschS. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol2003;21:15051512.

    • Search Google Scholar
    • Export Citation
  • 15.

    TandstadTDahlOCohn-CedermarkG. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol2009;2721222128.

    • Search Google Scholar
    • Export Citation
  • 16.

    SturgeonJFMooreMJKakiashviliDM. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol2011;59:556562.

    • Search Google Scholar
    • Export Citation
  • 17.

    KollmannsbergerCTyldesleySMooreC. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol2011;22:808814.

    • Search Google Scholar
    • Export Citation
  • 18.

    RustinGJMeadGMStenningSP. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol2007;25:13101315.

    • Search Google Scholar
    • Export Citation
  • 19.

    DaugaardGPetersenPMRorthM. Surveillance in stage I testicular cancer. APMIS2003;111:7683; discussion 83–75.

  • 20.

    ReadGStenningSPCullenMH. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol1992;10:17621768.

    • Search Google Scholar
    • Export Citation
  • 21.

    CollsBMHarveyVJSkeltonL. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int1999;83:7682.

    • Search Google Scholar
    • Export Citation
  • 22.

    CathomasRHartmannMKregeS. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie2011;34:5964.

    • Search Google Scholar
    • Export Citation
  • 23.

    SouchonRHartmannMKregeS. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol2011;187:158166.

    • Search Google Scholar
    • Export Citation
  • 24.

    SchmollHJJordanKHuddartR. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2010;21(Suppl 5):v147154.

    • Search Google Scholar
    • Export Citation
  • 25.

    van AsNJGilbertDCMoney-KyrleJ. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer2008;98:18941902.

    • Search Google Scholar
    • Export Citation
  • 26.

    VergouweYSteyerbergEWEijkemansMJ. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol2003;21:40924099.

    • Search Google Scholar
    • Export Citation
  • 27.

    BokemeyerCKuczykMASerthJ. Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J Cancer Res Clin Oncol1996;122:575584.

    • Search Google Scholar
    • Export Citation
  • 28.

    DivrikRTAkdoganBOzenHZorluF. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?J Urol2006;176:14241429; discussion 1429–1430.

    • Search Google Scholar
    • Export Citation
  • 29.

    SoganiPCPerrottiMHerrHW. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol1998;159:855858.

  • 30.

    MarotoPGarcia del MuroXAparicioJ. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol2005;16:19151920.

    • Search Google Scholar
    • Export Citation
  • 31.

    AlbersPSienerRKregeS. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol2008;26:29662972.

    • Search Google Scholar
    • Export Citation
  • 32.

    KollmannsbergerCMooreCChiKN. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol2010;21:12961301.

    • Search Google Scholar
    • Export Citation
  • 33.

    SteinerHZangerlFStohrB. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol2008;180:13481352; discussion 1352–1343.

    • Search Google Scholar
    • Export Citation
  • 34.

    RichieJP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol1990;144:11601163.

  • 35.

    WeissbachLBussar-MaatzRFlechtnerH. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol2000;37:582594.

    • Search Google Scholar
    • Export Citation
  • 36.

    StephensonAJBoslGJMotzerRJ. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol2007;25:55975602.

    • Search Google Scholar
    • Export Citation
  • 37.

    DonohueJPThornhillJAFosterRS. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol1995;153:8589.

    • Search Google Scholar
    • Export Citation
  • 38.

    RabbaniFSheinfeldJFarivar-MohseniH. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol2001;19:20202025.

    • Search Google Scholar
    • Export Citation
  • 39.

    WilliamsSDStableinDMEinhornLH. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med1987;317:14331438.

    • Search Google Scholar
    • Export Citation
  • 40.

    HorwichAStenningS. Initial chemotherapy for stage II testicular non-seminoma. World J Urol1994;12:148150.

  • 41.

    PeckhamMJHendryWF. Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. Br J Urol1985;57:763768.

    • Search Google Scholar
    • Export Citation
  • 42.

    VogelzangNJFraleyEELangePH. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol1983;1:171178.

  • 43.

    MotzerRJSheinfeldJMazumdarM. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol1995;13:27002704.

    • Search Google Scholar
    • Export Citation
  • 44.

    GrimisonPSStocklerMRThomsonDB. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst2010;102:12531262.

    • Search Google Scholar
    • Export Citation
  • 45.

    LogothetisCJSwansonDADexeusF. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol1987;5:906911.

    • Search Google Scholar
    • Export Citation
  • 46.

    KregeSBeyerJSouchonR. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol2008;53:497513.

    • Search Google Scholar
    • Export Citation
  • 47.

    EhrlichYBramesMJBeckSD. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?J Clin Oncol2010;28:531536.

    • Search Google Scholar
    • Export Citation
  • 48.

    BeckSDFosterRS. Management of the post chemotherapy subcentimeter residual mass: the case for observation. World J Urol2009;27:485488.

    • Search Google Scholar
    • Export Citation
  • 49.

    PanicekDMTonerGCHeelanRTBoslGJ. Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy. Radiology1990;175:499502.

  • 50.

    FossaSDAassNOusS. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol1989;142:12391242.

    • Search Google Scholar
    • Export Citation
  • 51.

    XiaoHSheinfeldJMotzerRJ. Adjuvant chemotherapy for testicular cancer. Surg Oncol Clin N Am1997;6:863878.

  • 52.

    KuczykMMachtensSStiefCJonasU. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). Int J Cancer1999;83:852855.

    • Search Google Scholar
    • Export Citation
  • 53.

    TonerGCPanicekDMHeelanRT. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol1990;8:16831694.

    • Search Google Scholar
    • Export Citation
  • 54.

    BanielJFosterRSGoninR. Late relapse of testicular cancer. J Clin Oncol1995;13:11701176.

  • 55.

    AlbersPGanzAHannigE. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol2000;164:381384.

  • 56.

    GeldartTRGaleJMcKendrickJ. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int2006;98:353358.

    • Search Google Scholar
    • Export Citation
  • 57.

    GietemaJAMeinardiMTSleijferDT. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol2002;13:16161620.

    • Search Google Scholar
    • Export Citation
  • 58.

    FossaSDStenningSPGerlA. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer1999;80:13921399.

    • Search Google Scholar
    • Export Citation
  • 59.

    LorchABeyerJBascoul-MolleviC. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol2010;28:49064911.

    • Search Google Scholar
    • Export Citation
  • 60.

    EinhornLHWilliamsSDChamnessA. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med2007;357:340348.

    • Search Google Scholar
    • Export Citation
  • 61.

    MotzerRJGellerNLTanCC. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer1991;67:13051310.

    • Search Google Scholar
    • Export Citation
  • 62.

    WardePSpechtLHorwichA. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol2002;20:44484452.

    • Search Google Scholar
    • Export Citation
  • 63.

    ChungPWDaugaardGTyldesleyS. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study [abstract]. J Clin Oncol2010;28(Suppl):Abstract 4535.

    • Search Google Scholar
    • Export Citation
  • 64.

    AparicioJMarotoPdel MuroXG. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol2011;29:46774681.

    • Search Google Scholar
    • Export Citation
  • 65.

    MotzerRJAgarwalNBeardC. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 12011. To view the most recent version of these guidelines visitNCCN.org.

    • Search Google Scholar
    • Export Citation
  • 66.

    BeardCJTravisLBChenMH. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer2013;119:27712777.

  • 67.

    OliverRTMeadGMRustinGJ. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol2011;29:957962.

    • Search Google Scholar
    • Export Citation
  • 68.

    FossaSDHorwichARussellJM. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol1999;17:1146.

    • Search Google Scholar
    • Export Citation
  • 69.

    MeadGMFossaSDOliverRT. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst2011;103:241249.

    • Search Google Scholar
    • Export Citation
  • 70.

    HorwichASleijferDTFossaSD. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol1997;15: 18441852.

    • Search Google Scholar
    • Export Citation
  • 71.

    SchmidbergerHBambergMMeisnerC. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys1997;39:321326.

    • Search Google Scholar
    • Export Citation
  • 72.

    ClassenJSchmidbergerHMeisnerC. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol2003;21:11011106.

    • Search Google Scholar
    • Export Citation
  • 73.

    WilderRBBuyyounouskiMKEfstathiouJA. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biop Phys2012;83:445452.

    • Search Google Scholar
    • Export Citation
  • 74.

    ClassenJSouchonRHehrTBambergM. Radiotherapy for early stages testicular seminoma: patterns of care study in Germany. Radiother Oncol2002;63:179186.

    • Search Google Scholar
    • Export Citation
  • 75.

    Garcia-del-MuroXMarotoPGumaJ. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol2008;26:54165421.

    • Search Google Scholar
    • Export Citation
  • 76.

    WardePHuddartRBoltonD. Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology2011;78:S435443.

    • Search Google Scholar
    • Export Citation
  • 77.

    HerrHWSheinfeldJPucHS. Surgery for a post-chemotherapy residual mass in seminoma. J Urol1997;157:860862.

  • 78.

    FlechonABompasEBironPDrozJP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol2002;168:19751979.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 63 63 4
PDF Downloads 24 24 2
EPUB Downloads 0 0 0